Lota S. Zoth - Dec 21, 2022 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Dec 21, 2022
Transactions value $
$0
Form type
4
Date filed
12/23/2022, 06:00 PM
Previous filing
May 18, 2022
Next filing
Feb 13, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +25K $0.00 25K Dec 21, 2022 Common Stock 25K $8.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest on date of next annual general meeting following grant date of December 21, 2022.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.